Results 231 to 240 of about 477,001 (311)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Enhancing cervical squamous cell carcinoma diagnosis under distribution shift via domain-adaptive representation learning. [PDF]

iScience
Huang Z, Liu Y, Jin S, Wang Y, Fu M, Ouyang J, Yu D, Zhu T, Zeng F, Pan X, Ye J, Wang J, He X, Cheng X, Zhao M, He Y, Zhang H, Hu B.   +17 more
europepmc   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Growth Performance and Carcass Quality of Crossbred Holstein × Beef Heifers and Steers Fed High-Solid Milk in the Preweaning Period. [PDF]

Animals (Basel)
Carrillo-Moreno E, Carrillo-Moreno DI, Carrillo-Castellanos E, Pérez-Rebolloso E, Mellado M.   +4 more
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

CT Attenuation Thresholds for Grading Hepatic Steatosis in Adults with Overweight or Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Diagnostics (Basel)
Góngora-Chan P, Jimeno-Figueroa RE, Williams-Jacquez D, Chaurand-Lara M, Gutiérrez-Solis AL, Avila-Nava A, Chim-Aké R, Valdivieso-Jiménez JA, Torres-Erazo DS, Medina-Vera I, Guevara-Cruz M, Lugo R.   +11 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Pattern-Anchored Diagnosis of Oral Epithelial Dysplasia: A Position Paper From COST Action INTERCEPTOR Working Group 2. [PDF]

Head Neck Pathol
Khurram SA, Hunter KD, Odell EW, Tekkeşin MS, Lingen M, Vargas PA, Kujan O, Costea DE, Bossi P, Saintigny P, Koljenović S.   +10 more
europepmc   +1 more source